Chris Howerton
Stock Analyst at Jefferies
(2.55)
# 2,059
Out of 4,814 analysts
74
Total ratings
42.37%
Success rate
13.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $4.56 | +75.63% | 5 | Jan 2, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $23.10 | +241.99% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.01 | +296.04% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $1 | $0.52 | +90.80% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $1.71 | +20,484.80% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $4.41 | +16,226.53% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.40 | -64.29% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $9.63 | +3.84% | 1 | Feb 8, 2023 | |
| MEIP MEI Pharma | Downgrades: Underperform | $8 → $2 | $1.91 | +4.71% | 3 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $7.96 | +38.28% | 3 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $70 → $40 | $18.04 | +121.73% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $28.50 | +114.04% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $103.02 | -12.64% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $4.30 | +179.07% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $126 | $1.28 | +9,743.75% | 1 | Dec 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.89 | +2,148.71% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $18.97 | +247.92% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $4.51 | +387.80% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.53 | +1,272.55% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $0.84 | +2,505.40% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.42 | +1,519.72% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $14.40 | +45.88% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $4 → $29 | $0.37 | +7,643.66% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.00 | +5,922.89% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $62.94 | -74.58% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $45.56 | -40.74% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $0.09 | +27,391.41% | 1 | May 26, 2020 |
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $4.56
Upside: +75.63%
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $23.10
Upside: +241.99%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.01
Upside: +296.04%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $1
Current: $0.52
Upside: +90.80%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $1.71
Upside: +20,484.80%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $4.41
Upside: +16,226.53%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.40
Upside: -64.29%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $9.63
Upside: +3.84%
MEI Pharma
Feb 8, 2023
Downgrades: Underperform
Price Target: $8 → $2
Current: $1.91
Upside: +4.71%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $7.96
Upside: +38.28%
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $18.04
Upside: +121.73%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $28.50
Upside: +114.04%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $103.02
Upside: -12.64%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $4.30
Upside: +179.07%
Dec 13, 2021
Maintains: Buy
Price Target: $101 → $126
Current: $1.28
Upside: +9,743.75%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $0.89
Upside: +2,148.71%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $18.97
Upside: +247.92%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $4.51
Upside: +387.80%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.53
Upside: +1,272.55%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $0.84
Upside: +2,505.40%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $1.42
Upside: +1,519.72%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $14.40
Upside: +45.88%
Aug 11, 2020
Upgrades: Buy
Price Target: $4 → $29
Current: $0.37
Upside: +7,643.66%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.00
Upside: +5,922.89%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $62.94
Upside: -74.58%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $45.56
Upside: -40.74%
May 26, 2020
Initiates: Buy
Price Target: $24
Current: $0.09
Upside: +27,391.41%